BRIEF—Deinove and Calibr to explore therapeutic potential of rare bacteria

Parisian biotech Deinove and a non-profit drug discovery group Calibr are to collaborate to explore the anti-infectious potential of the French firm’s bacterial collection.

As part of this collaboration, Deinove will provide Calibr with bacterial extracts, which will be investigated for their potential in the treatment of neglected parasitic and infectious diseases, such as tuberculosis or malaria.

Calibr’s principal investigator Case McNamara said: "We are committed to discovering new treatments for diseases neglected by pharmaceutical research, which represent a real public health challenge for developing countries. The Deinove bacterial collection includes several rare microorganisms and we look forward to assessing their potential in this area."